duced joint swelling was mediated primarily via PAR 2 activation, since the response to exogenous application of trypsin and tryptase was absent in PAR 2 knockout mice. Furthermore, serine proteinase inhibitors were effective anti-inflammatory agents in this model. Disrupting proteolytic activation of PAR 2 using antiserum (B5) directed to the receptor cleavage/activation site also attenuated C/K-induced inflammation, as did the similarly targeted PAR 2 monoclonal antibody SAM-11. Finally, we report the activity of a novel small molecule PAR 2 antagonist, N 1 -3-methylbutyryl-N 4 -6-aminohexanoyl-piperazine (ENMD-1068) , that dose dependently attenuated joint inflammation. Our findings represent a major advance in collectively identifying PAR 2 as a novel target for the future treatment of arthritis.
Proteinase-activated receptor (PAR)-2 is one of a unique subfamily of G protein-coupled receptors originally cloned from murine and human sources (Nystedt et al., 1994 (Nystedt et al., , 1995 Bohm et al., 1996) . It is activated by a novel mechanism involving the proteolysis of the receptor N terminus to expose a "tethered ligand" sequence. This proteolytically revealed N-terminal tethered ligand then binds to and activates the receptor, resulting in signaling and internalization of the receptor complex (for reviews, see Macfarlane et al., 2001; Hollenberg and Compton, 2002; Ossovskaya and Bunnett, 2004) . Four members of the PAR family, PAR 1 , PAR 2 , PAR 3 , and PAR 4 , have been cloned and characterized to date (Macfarlane et al., 2001; Hollenberg and Compton, 2002; Ossovskaya and Bunnett, 2004) . Unlike other members of the PAR family, where the primary activating proteinase is thrombin, PAR 2 is preferentially activated by trypsin and related serine proteinases, including mast cell tryptase (Nystedt et al., 1994; Corvera et al., 1997; Molino et al., 1997) . In addition to this cleavage mechanism, PAR 2 can also be activated selectively by the application of synthetic peptides modeled on the sequence of the tethered ligand such as the human sequence SLIGKV-NH 2 , and the more potent murine variant, SLI-GRL-NH 2 (Blackhart et al., 1996; Hollenberg et al., 1997; Al-Ani et al., 1999; Ferrell et al., 2003) .
PAR 2 has been implicated in inflammatory responses, and its actions include increased vascular permeability (Kawabata et al., 1998) , leukocyte infiltration (Vergnolle et al., 1999) , and smooth muscle relaxation (Al-Ani et al., 1995) . There has also been increasing interest in PAR 2 as a mediator of nociception (Vergnolle et al., 2001a) and neurogenic inflammation (Steinhoff et al., 2000) , with the latter study demonstrating coexpression of PAR 2 on sensory nerves along with substance P and calcitonin generelated peptide. Because the edema formation induced by SLIGRL-NH 2 was blocked by neuropeptide antagonists, or by depleting sensory nerve endings with capsaicin, PAR 2 was concluded to mediate neurogenic inflammation via release of sensory neuropeptides. Inflammation in the joint has also previously been reported to involve a neurogenic component mediated by sensory neuropeptide release (Lam and Ferrell, 1991) , although it is not known whether this process involves PAR 2 . We recently demonstrated that administration of specific PAR 2 agonists induced joint swelling and hyperemia, both cardinal signs of inflammation (Ferrell et al., 2003) . Moreover, chronic joint inflammation is attenuated in PAR 2 knockout mice (Ferrell et al., 2003) , arguing for a critical proinflammatory role for this receptor in the joint. From a clinical perspective, the key question to be addressed in this study is whether PAR 2 presents a new therapeutic target for the treatment of arthritis. An acute model of arthritis was used to establish proof of concept, assessing various approaches of preventing PAR 2 activation from genomic intervention to use of a novel PAR 2 antagonist (Fig. 1 ).
Materials and Methods

Animals. Wild-type (PAR 2
ϩ/ϩ ) C57BL/6J and PAR 2 -deficient (PAR 2 Ϫ/Ϫ ) mice (Ferrell et al., 2003) , body weight 25 to 30 g, were used. All procedures were performed in accordance with United Kingdom regulations.
Joint Inflammation. To establish proof of principle by multiple therapeutic interventions, an acute model of inflammation was used. Knee joint diameter was measured using calipers (Kroeplin GmbH, Schlü chtern, Germany) before and after inflammation was induced by 20 l of intra-articular injection of 2% -carrageenan and 4% kaolin (C/K; Sigma Chemical, Poole, Dorset, UK) in saline under anesthesia (O 2 , N 2 O, 2% halothane; withdrawal reflex absent). Measurements were reproducible with coefficient of variation Յ2%.
PAR 2 Antagonist Characterization. The PAR 2 antagonist ENMD-1068 was designed as a disubstituted piperazine whose side chains were based upon the results of peptide antagonist screening. The antagonist activity of ENMD-1068 was characterized using a calcium mobilization assay . Cells were loaded with 5 M Fluo-4 in Hanks' balanced salt solution assay buffer (20 mM HEPES pH 7.4, 1 mM MgSO 4 , 1 mM CaCl 2 , and 2.5 mM probenecid) for 40 min. After rinsing, cells were incubated with increasing concentrations of ENMD-1068 for 30 to 40 min before addition of PAR agonists or PAR 2 -activating proteinase. The antagonist was assessed using both human (SLIGKV-NH 2 ) and murine (SLIGRL-NH 2 ) agonist peptides.
Western Blotting. Protein extracts derived from 100 ng of tissue were prepared from inflamed (C/K) and control synovium using standard procedures, separated by SDS-polyacrylamide gel electrophoresis, and transferred onto nitrocellulose membrane (GE Healthcare, Little Chalfont, Buckinghamshire, UK) in a buffer containing 20 mM Tris, 20 mM glycine, and 20% methanol at a constant voltage of 100 V for 25 min. Residual binding sites were blocked, and the membrane was incubated with a PAR 2 monoclonal primary antibody (SAM-11; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) at a 1:1000 dilution. This antibody is directed to amino acids 37 to 50 (SLIGKVDGTSHVTG) of hPAR 2 . After a further washing period the membrane was incubated with goat anti-mouse IgG conjugated to horseradish peroxidase (BD Biosciences, Oxford, UK) at a 1:2000 dilution for 1 h. The membrane was developed using ECL Plus, and antibody detection was conducted with HyperFilm (GE Healthcare).
B5 Antiserum. A polyclonal antiserum, B5 (Kong et al., 1997; Al-Ani et al., 1999) , raised to a peptide corresponding to the rat PAR 2 sequence 30 GPNSKGR2rSLIGRLDT 46 P-yggc, coupled to keyhole limpet hemocyanin (2, trypsin cleavage site; yggc added for conjugation). The peptide sequence SKGRSLIGRL of the immunogen corresponds to the sequence of murine PAR 2 incorporating the tethered ligand. B5 detects both the preactivated and activated forms of PAR 2 (i.e., total PAR 2 immunoreactivity) in various species, including rat and mouse (Wang et al., 2003) . The antiserum (1:1000 dilution) was injected (20 l) into the knee joint 5 min before administration of C/K. As a control, nonimmune rabbit serum, in the same total protein concentration, was administered in separate animals.
Immunohistochemistry. To confirm PAR 2 selectivity, cryopreserved brains from PAR 2 ϩ/ϩ and PAR 2 Ϫ/Ϫ mice were analyzed using B5 since all four PARs have been detected in the central nervous system (Striggow et al., 2001) . Sections (6 m) were acetone fixed, treated to quench endogenous peroxidase, and then incubated with blocking buffer. Sections were incubated with B5 at 1:1000 (12 h; 4°C). Endogenous biotin was blocked using an Avidin/Biotin blocking kit (Vector Laboratories, Peterborough, UK). Biotinylated secondary antibody (Santa Cruz Biotechnology, Inc.) was applied for 30 min and then incubated with peroxidase-conjugated streptavidin for 30 min. Antigen-antibody complexes were visualized using 3,3Ј-diaminobenzadine. Slides were counterstained with Mayer's hematoxylin and mounted in di-n-butyl phthalate polystyrene xylene.
Small Interfering RNA. Small interfering RNA (siRNA) sequences were designed as described previously (Elbashir et al., 2001) . A sequence 5Ј-AA(N19) UU-3Ј was selected from the open reading frame of the cDNA sequence of the PAR 2 gene ϳ100 nucleotides downstream of the start codon. This sequence, siRNA PAR2 (AAU GGC AUG GCC CUC UGG AUC), and a scrambled sequence derived from it, siRNA CON (AAG UCG UGA CGC UCC GUG CAU), were synthesized (Dharmacon Research, Inc., Lafayette, CO). Both sequences were checked (www.ncbi.nlm.nih.gov/BLAST) to ensure that only the PAR 2 gene was targeted by the siRNA PAR2 and that the siRNA CON sequence was nonspecific. Either siRNA PAR2 or siRNA CON was injected i.p. at a dose of 2 nmol/day for 3 days before C/K administration. 
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In Vitro Studies. NCTC2544 cells, expressing hPAR 2 (clone G) were prelabeled with 1Ci/ml [ 3 H]myoinositol for 24 h in serum-free medium. Cells were preincubated with 10 mM LiCl for 30 min and stimulated for a further 40 min with trypsin (50 nM) or the PAR 2 agonist SLIGKV-NH 2 (100 M). Reactions were terminated and [ 3 H]inositol phosphates extracted using 1 ml of methanol/0.5 ml of chloroform. Water-soluble inositol phosphates were separated from phospholipids by addition of 0.5 ml of chloroform and 0.8 ml of H 2 O followed by centrifugation. Total inositol phosphates were then assayed by ion exchange chromatography on Dowex-1 columns (Plevin et al., 1990) and measured by liquid scintillation counting.
Drugs. Trypsin (catalog no. T1426), soybean trypsin inhibitor (catalog no. T9003), thrombin (catalog no. T6634), and nonimmune rabbit serum were obtained from Sigma Chemical. ␤-Tryptase was expressed in Pichia pastoris (Niles et al., 1998) and purified to apparent homogeneity (specific activity Ͼ90% of the theoretical value). 4-Amidinophenylpyruvic acid (APPA) was a gift from J. Stü rzebecher (Germany). SLIGKV-NH 2 was obtained from Neosystem (Strasbourg, France).
Statistics. Data are expressed as mean Ϯ S.E.M., and comparisons were performed using two-tailed t test or one-or two-way repeated measures ANOVA, with Bonferroni post hoc testing (SigmaStat; SPSS Inc., Chicago, IL). Swelling was evaluated as change in joint diameter as percentage of preinjection values.
Results
PAR 2 Inhibition at the Genomic Level. Intra-articular injection of C/K resulted in progressive knee joint swelling in PAR 2 ϩ/ϩ mice, a response significantly (p ϭ 0.014; two-way ANOVA; n ϭ 4 -6) attenuated in PAR 2 Ϫ/Ϫ mice ( Fig. 2A) . The involvement of PAR 2 in acute joint inflammation was further highlighted by immunoblot analysis of PAR 2 ϩ/ϩ mouse synovium, which showed a marked up-regulation of PAR 2 protein expression in the inflamed joint in a time-dependent manner ( Fig. 2A, inset ). Immunoblot analysis also revealed an upregulation of several glycosylated PAR 2 species (in the 50-to 100-kDa range) known to be synthesized by cells or tissues, in agreement with the findings of Compton et al. (2002) .
Using another genomic approach, siRNA PAR2 was administered i.p. to PAR 2 ϩ/ϩ mice 3 days before induction of acute joint inflammation. This down-regulated PAR 2 as confirmed by immunoblot analysis (Fig. 2B, inset) , with a corresponding significant (p Ͻ 0.0001; two-way ANOVA; n ϭ 8 -11) reduction of joint swelling (Fig. 2B ). siRNA CON had minimal effect on PAR 2 expression relative to siRNA PAR2 treatment (Fig.  2B, inset) . In contrast to siRNA PAR2 treatment, siRNA CON did not reduce joint swelling (p ϭ 0.09), with the two siRNA treatments differing significantly (p Ͻ 0.0001; Bonferroni; n ϭ 8 -11).
PAR 2 Inhibition by Proteinase Suppression. Intraarticular injection of trypsin (210 mol) in PAR 2 ϩ/ϩ mice caused a rapid increase in knee joint swelling, peaking at approximately 4 h and slowly subsiding thereafter (Fig. 3A) . This effect is specific for PAR 2 as the same procedure repeated in PAR 2 Ϫ/Ϫ mice was ineffective. Likewise, intraarticular injection of human ␤-tryptase (5 g) also resulted in knee joint swelling over a comparable time course (Fig. 3B) . Again, this effect is specific for PAR 2 because ␤-tryptase had no effect in PAR 2 Ϫ/Ϫ mice. In both cases, the responses in PAR 2 ϩ/ϩ mice were dose-dependent (data not shown). To investigate the ability of trypsin to activate PAR 2 , further experiments were performed in NCTC2544 cells expressing human PAR 2 . PAR 2 activation by trypsin (50 nM) in these cells, mimicked by the PAR 2 -activating peptide SLIGKV-NH 2 , resulted in an increase in the intracellular levels of inositol-1,4,5-trisphosphate, an effect that was significantly (p Ͻ 0.0001; Bonferroni; n ϭ 3) and dose dependently inhibited by soybean trypsin inhibitor (SBTI; Fig. 3C ). The effect of SBTI did not involve receptor blockade, since administration of the human PAR 2 -activating peptide SLIGKV-NH 2 Fig. 2 . Role for PAR 2 in acute joint inflammation. A, change in knee joint diameter after intra-articular injection of C/K in wild-type mice (ϩ/ϩ) compared with mice with PAR 2 gene disruption (Ϫ/Ϫ). Changes are expressed as percentages relative to preinjection values. The acute inflammatory response in the PAR 2 ϩ/ϩ mice (n ϭ 6) is characterized by progressive knee joint swelling over 24 h, a response significantly blunted in PAR 2 Ϫ/Ϫ mice (n ϭ 4). Inset shows Western immunoblot of PAR 2 protein at approximately 55 kDa. PAR 2 protein is present in uninflamed synovium of the PAR 2 ϩ/ϩ mouse before injection (0 h), but it up-regulates in a time-dependent manner after C/K administration. Several glycosylated PAR 2 receptor species (ϳ100 kDa) are also up-regulated. Samples prepared with 100 ng of tissue dry weight. B, i.p. administration of siRNA PAR2 (n ϭ 11) to PAR 2 ϩ/ϩ mice 2 days before intra-articular injection of C/K effectively reduced PAR 2 protein expression in the inflamed joint (inset), with a corresponding significant reduction of joint swelling. Scrambled siRNA (siRNA CON ; n ϭ 10) neither reduced PAR 2 expression (inset) nor reduced joint swelling significantly (n ϭ 8 for C/K group; means Ϯ S.E.M.; see PAR 2 Inhibition at the Genomic Level for statistics).
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at ASPET Journals on July 10, 2017 jpet.aspetjournals.org resulted in PAR 2 activation and an elevation of inositol-1,4,5-trisphosphate irrespective of the SBTI dose. The proinflammatory effects of trypsin and ␤-tryptase suggested that such serine proteinases might participate in C/K-induced joint inflammation. This possibility was therefore investigated using serine proteinase inhibitors. Preadministration of soybean trypsin inhibitor (5 mg), which can block a number of trypsin family members, significantly (p Ͻ 0.0001; Bonferroni; n ϭ 4 -5) inhibited C/K-induced joint swelling. Likewise, APPA (5 g), a tryptase inhibitor (Stü rzebecher et al., 1992; Sommerhoff et al., 2000) that can also inhibit other serine proteinases, was even more effective (Fig. 3D) at attenuating the inflammatory response triggered by C/K (p Ͻ 0.0001; Bonferroni; n ϭ 4 -5).
PAR 2 Inhibition by Occluding the Tethered Ligand. To first check the specificity of B5 for PAR 2 , we examined the effect of this antiserum on PAR 1 activation. Thrombin is known to activate PAR 1 , -3 , and -4 , but not PAR 2 , which is preferentially activated by other serine proteinases, such as trypsin. We therefore examined the effect of intra-articular injection of thrombin (20 units) on joint swelling. Thrombin induced modest swelling (7.5 Ϯ 2%), but this was not significantly (p ϭ 0.57; two-way ANOVA; n ϭ 4) inhibited by prior administration of B5 (Fig. 4A) , demonstrating pharmacologically the specificity of B5 for PAR 2 . This result was confirmed further by immunohistochemical analysis of PAR 2 expression using B5 in brain as a control tissue known to express all four PARs (Striggow et al., 2001) . Immunohistochemical analysis revealed PAR 2 expression in neurons of the PAR 2 ϩ/ϩ mouse, but no staining was evident in the PAR 2 Ϫ/Ϫ mouse (Fig. 4B) , despite the presence of PAR 1 , PAR 3 , and PAR 4 in the latter.
Having established the specificity of B5 antiserum for PAR 2 , experiments were then performed to determine whether prevention of receptor cleavage and activation by the revealed tethered ligand using B5 would attenuate the proinflammatory role of PAR 2 in this acute model of joint inflammation. Prior intra-articular injection of the B5 antiserum substantially reduced the acute inflammatory response to C/K (Fig. 4C) , the 4-fold reduction being highly significant compared with C/K alone (p Ͻ 0.0001; Bonferroni; n ϭ 4 -6). Prior administration of nonimmune serum did not significantly attenuate the inflammatory response (p ϭ 0.3; Bonferroni; n ϭ 4 -6). The attenuated response in the presence of the B5 antiserum was also significantly different (p Ͻ 0001; Bonferroni; n ϭ 6) from inflammation observed in the presence of nonimmune serum (Fig. 4C) . SAM-11, a monoclonal antibody to human PAR 2 that targets the residues SLIGXXD in common with B5, also significantly (p Ͻ 0.0001; two-way ANOVA; n ϭ 4) and dose dependently attenuated joint swelling (Fig. 4D) , with both doses of antibody differing from vehicle treatment (p Ͻ 0.0001; Bonferroni; n ϭ 4) and from each other (p Ͻ 0.002; Bonferroni; n ϭ 4). Together with the B5 studies, these results suggest that proteinase activation of PAR 2 via its revealed tethered ligand is necessary for its proinflammatory role.
PAR 2 Inhibition by Receptor Antagonism. ENMD-1068 is a novel selective PAR 2 antagonist, based on a disubstituted piperazine (Fig. 5A) , whose selectivity was confirmed both in vitro and in vivo. Figure 5B shows a ϩ/ϩ mice results in rapid knee joint swelling, an effect absent in PAR 2 Ϫ/Ϫ mice (n ϭ 4/group). B, similarly, intraarticular injection of ␤-tryptase (5 mg) produces knee joint swelling in PAR 2 ϩ/ϩ but not PAR 2 Ϫ/Ϫ mice (n ϭ 4/group). C, inositol accumulation in hPAR 2 -expressing NCTC2544 cells in response to administration of 50 nM trypsin or 100 M PAR 2 agonist SLIGKV-NH 2 in the presence of increasing concentrations of SBTI. The trypsin response is dose dependently reduced by SBTI, whereas the response to SLIGKV-NH 2 is unaffected. D, prior intra-articular injection of SBTI (n ϭ 4) dose dependently inhibits knee joint swelling induced 24 h after intra-articular injection of C/K. Likewise, the tryptase inhibitor APPA (n ϭ 4) is also effective at inhibiting the inflammatory response (n ϭ 5 for C/K group).
representative inhibition study using murine Lewis lung carcinoma (LLC) cells stimulated with 200 M SLIGKV-NH 2 . ENMD-1068 dose dependently inhibited calcium signaling, this being complete at 5 mM. Similar inhibition was observed on both human and murine cells stimulated with either human or murine agonist peptide (data not shown). Proteolytically activated PAR 2 studies were performed using trypsin, and Fig. 5C shows complete inhibition of trypsin signaling in murine LLC cells at 5 mM. ENMD-1068 had no effect on the proteolytic activity of trypsin (data not shown). Inhibition of trypsin signaling was also observed in human cell lines (data not shown). ENMD-1068 specificity was demonstrated by assessing signaling using the PAR 1 agonist peptide TFLLRN (Fig. 5D ) and ATP (data not shown) in the presence of increasing concentrations of ENMD-1068. In all cases, no inhibition of calcium signaling was observed with ENMD-1068. Finally, ENMD-1068 did not inhibit murine platelet aggregation stimulated by the addition of thrombin, demonstrating that up to 5 mM ENMD-1068 has no inhibitory activity against thrombin-mediated PAR 3 and PAR 4 signaling (data not shown).
Having demonstrated the in vitro selectivity of ENMD-1068, we next confirmed its selectivity in vivo. The observation that C/K-induced swelling was not completely abolished in PAR 2 Ϫ/Ϫ mice ( Fig. 2A) , presented an opportunity to assess specificity by administering the antagonist before induction of inflammation in these mice. ENMD-1068 (4 mg i.p.) in PAR 2 Ϫ/Ϫ mice had no significant effect across 24 h (p ϭ 0.544; two-way ANOVA; n ϭ 3-6) compared with vehicle-treated PAR 2 Ϫ/Ϫ mice (Fig. 5E ), confirming ENMD-1068 is not influencing inflammatory pathways other than those mediated via PAR 2 . The specificity of this compound was further confirmed (Fig. 5E ) by the observation that ENMD-1068 (4 mg i.p.) had no effect on thrombin-mediated knee joint swelling over 48 h (p ϭ 0.99; two-way ANOVA; n ϭ 4 -5).
The culmination of this study is the key finding that joint inflammation was dose dependently attenuated by prior i.p. administration of ENMD-1068 (Fig. 6) , this effect being highly significant (p Ͻ 0.0001; two-way ANOVA; n ϭ 5-6). Compared with i.p. injection of vehicle, joint swelling was significantly reduced by ENMD-1068 at both the 1-and 4-mg doses (p Ͻ 0.0001 in both cases; Bonferroni; n ϭ 5-6), which also differed from each other (p ϭ 0.0065; Bonferroni; n ϭ 5-6).
Discussion
Investigation of the pathophysiological roles for PAR 2 has been limited to date by the lack of a selective receptor antagonist. The current study presents the first evidence demonstrating the inhibition of acute joint inflammation by multiple strategies targeting PAR 2 (Fig. 1) , including the use of a novel PAR 2 antagonist. PAR 2 has previously been reported to mediate acute inflammatory responses by neurogenic (Steinhoff et al., 2000) and non-neurogenic mechanisms (Damiano et al., 1999) . Several lines of evidence are presented in the current murine study to demonstrate a role for PAR 2 in acute knee joint inflammation. First, the inflammatory response in the acute model of arthritis was substantially attenuated in PAR 2 -deficient mice, supporting a key role for this receptor in inflammation. Second, the expression of PAR 2 protein in Fig. 4 . Selectivity of B5 antiserum for PAR 2 . A, intraarticular administration of thrombin in PAR 2 ϩ/ϩ mice (n ϭ 4/group) induced knee joint swelling that was not significantly altered by coadministration of B5 antiserum (20 l; 1:1000 dilution). B, staining for PAR 2 in mouse brain using B5 antiserum. PAR 2 immunoreactivity is present in neurons (red arrowheads) of wildtype (ϩ/ϩ) but not of PAR 2 gene-disrupted (Ϫ/Ϫ) mice. PAR 2 staining is also evident in blood vessels of PAR 2 ϩ/ϩ but absent in PAR 2 Ϫ/Ϫ mice (black arrows). Scale bar, 100 m. C, pretreatment with B5 antiserum (20 l; 1:1000 dilution) substantially attenuates the response to C/K-induced inflammation. C/K alone (n ϭ 4) resulted in a 26 Ϯ 4% increase in joint diameter at 24 h that was significantly attenuated by B5 (6 Ϯ 2%; n ϭ 6) at this time point. Nonimmune serum (n ϭ 6) did not significantly alter the response to CK at any time point. D, dose-dependent inhibition of joint swelling was also obtained using a monoclonal antibody to PAR 2 (SAM-11) at 5 and 10 ng (n ϭ 5/group).
Therapeutic Potential of PAR 2 Inhibition murine articular tissue was substantially up-regulated during acute joint inflammation. Preventing such up-regulation by post-transcriptional gene silencing of PAR 2 , using siRNA designed against the receptor sequence, resulted in inhibition of joint inflammation, supporting the findings of the PAR 2 Ϫ/Ϫ murine studies. The significant reduction of joint swelling in the PAR 2 Ϫ/Ϫ animals suggested that preventing PAR 2 activation would have significant anti-inflammatory potential. Indeed, inhibition of joint inflammation by preventing PAR 2 activation using 1) proteinase inhibitors, 2) antibodies targeted against PAR 2 , and 3) an antagonist for the ligand binding domain on PAR 2 together provide proof of principle that PAR 2 plays a key role in joint inflammation via receptor up-regulation, proteinase cleavage, and endogenous activation by the revealed tethered ligand.
Post-transcriptional gene silencing using siRNA technology proved an effective means of reducing synovial expression of PAR 2 , thereby inhibiting joint inflammation (Fig. 2B) .
Although siRNA sequences have been administered in vivo with success previously (Soutschek et al., 2004) , this study is the first to show both that intraperitoneal administration of siRNA can be effective in reducing levels of targeted proteins within joint tissues and that such technology can be applied to down-regulate PAR 2 expression specifically, with potential therapeutic value. Further work is required to delineate which cells express PAR 2 in the inflamed joint and whether the siRNA-induced reduction in expression was in the resident articular and/or infiltrating inflammatory cells.
Trypsin is well recognized as a proteinase activator of PAR 2 , as corroborated in the present study on murine synovium. Significantly, trypsin as well as ␤-tryptase were able to mimic C/K-induced joint swelling, an effect that was abrogated by inhibitors of these proteolytic enzymes. It was also significant that neither trypsin nor ␤-tryptase caused joint swelling in PAR 2 null animals, a result that is entirely in keeping with a lack of effect of these proteinases in other Ϫ/Ϫ mice (Ϫ/Ϫ) pretreated with vehicle (0.9% NaCl i.p.; n ϭ 3) gave a small inflammatory response at the 24-h time point that was unaffected (p ϭ 0.46; unpaired t test) by pretreatment (4 mg i.p.) with ENMD-1068 (n ϭ 6). Likewise, intraarticular injection of 20 units of thrombin in vehicle-treated PAR 2 ϩ/ϩ mice (ϩ/ϩ; n ϭ 4) elicited a modest degree of knee joint swelling by 24 h that was not inhibited (p ϭ 0.47 unpaired t test) by ENMD-1068 (4 mg i.p.) pretreatment (n ϭ 5).
inflammatory models using PAR 2 -deficient animals (Vergnolle et al., 2001b ). An endogenous source of trypsinlike enzymes in the murine joint has not yet been established, although it has been shown in the rat lung that PAR 2 colocalizes immunohistochemically with an unidentified trypsin family member in epithelial and endothelial cells (Cocks and Moffatt, 2000) . Extrapancreatic trypsin can also be found in a number of sites in humans, such as in human dermal endothelial cells, wherein trypsinogen mRNA has been detected (Shpacovitch et al., 2002) . Furthermore, members of the trypsin family are now known to be up-regulated in the setting of a murine model of infectious colitis, which accounts for the inflammatory response mediated by PAR 2 (Hansen et al., 2005) . Mast cells are found in large numbers in the inflamed human rheumatoid synovium (Woolley and Tetlow, 2000) and can be implicated in PAR 2 -mediated inflammation in humans since these cells release serine proteinases such as tryptase. Tryptase, an activator of PAR 2 (Corvera et al., 1997; Molino et al., 1997) , is known to be present in human mast cells and is thus an endogenous candidate for PAR 2 cleavage/activation within the joint in humans. Murine connective tissue mast cells express mouse mast cell proteinase-6 and -7 (MMCP-6 and -7), which have approximately 75% amino acid sequence identity with human mast cell tryptases (Reynolds et al., 1991) , but it cannot be excluded that other serine proteinases may have contributed to the inflammation generated by the C/K stimulus. Remarkably, both soybean trypsin inhibitor, which can potentially block a number of the murine trypsins, and APPA, another serine proteinase inhibitor that can target various serine proteinases, including human tryptase, were effective in attenuating C/K-induced joint inflammation. Thus, proteinase inhibitors themselves may represent an effective therapeutic modality for arthritis. Interestingly, the joint swelling induced by intra-articular application of either trypsin or tryptase was effectively abolished in PAR 2 Ϫ/Ϫ mice (Fig. 3, A and B) , arguing that the inflammatory actions of both potent proteinases seem to be mediated primarily via PAR 2 activation. In this context, both proteinases provide valuable experimental tools for cleavage-mediated endogenous activation of the receptor. However, other serine proteinases such as human leukocyte elastase and cathepsin G (Uehara et al., 2003) may also play a PAR 2 -activating role in the setting of arthritis.
Although the B5 antiserum was originally raised against rat PAR 2 (Kong et al., 1997) , the sequence of the immunizing rat peptide is the same in much of its sequence as the comparable murine sequence. The specificity of the B5 antiserum for murine PAR 2 was confirmed immunohistochemically by the selective positive staining in the brain of PAR 2 ϩ/ϩ mice, but not PAR 2 Ϫ/Ϫ mice, which express PAR 1 , PAR 3 , and PAR 4 , but clearly not PAR 2 in this tissue. The selectivity of B5 for PAR 2 inhibition was confirmed further by the observation that the antiserum did not significantly inhibit thrombininduced joint swelling. The effectiveness of B5 in detecting murine PAR 2 protein is because of the close homology of PAR 2 between rat and mouse (97% sequence identity on the DNA level; BLAST). The selectivity of SAM-11 for human PAR 2 has previously been established (Molino et al., 1998) , and for the present study it was also confirmed immunohistochemically in murine tissues (data not shown).
Importantly, this study provides the first demonstration that antibodies raised against the cleavage site on the tethered ligand, thereby inhibiting receptor activation, have significant anti-inflammatory action (Fig. 4, C and D) . However, the therapeutic potential of this approach is limited by the need for local intra-articular administration to ensure efficacy. The small molecule antagonist for PAR 2 , ENMD-1068, allowed a more traditional pharmacological approach to blocking PAR 2 activation and offers considerably greater potential for future anti-inflammatory therapy because this compound, when administered systemically, powerfully and dose dependently reduced knee joint swelling (Fig. 6) . ENMD-1068 inhibits PAR 2 selectively in vitro and in vivo (Fig. 5) , although requiring relatively high concentrations, possibly reflecting low receptor affinity. This is reminiscent of peptides described previously that inhibited PAR 2 activation by trypsin but again with low potency (Al-Ani et al., 2002) . Even so, ENMD-1068 and analogs provide good "lead" compounds for future development of therapeutically valuable agents.
Using multiple strategies to prevent PAR 2 activation (Fig.  1) , including the first use of a receptor antagonist, our findings support the unifying conclusion that PAR 2 is a therapeutic target in the treatment of inflammatory joint disease. This is the first study to establish such proof of concept and identifies antagonists and/or antibodies targeting PAR 2 as potentially powerful anti-inflammatory agents for treatment of arthritis. Fig. 6 . Antagonism of PAR 2 . The i.p. administration of ENMD-1068 (1 and 4 mg; n ϭ 5 and 6, respectively) in wild-type mice dose dependently reduced CK-induced joint swelling, these effects being highly significant (p Ͻ 0.0001) compared with vehicle (n ϭ 6).
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